Overview


According to FutureWise analysis the market for Kidney-Renal Cancer Drugs Market in 2023 is US$ 6.65 billion, and is expected to reach US$ 10.31 billion by 2031 at a CAGR of 5.62%.

The kidney cancer also called renal cell adenocarcinoma or kidney cancer is a condition in which malignant (cancerous) cells are found within the lining tubules (very tiny tubes) of the kidney. Two kidneys are located above the waist, one on each side of the backbone. The kidneys have tiny tubules that filter and cleanse the blood. Each kidney sends urine through a tube called a "ureter" into the bladder. The renal pelvis is the part of the kidney that collects urine and drains it to ureters. This cancer is distinct from renal cell carcinoma.

After cardiovascular diseases, cancer has now become the second leading cause of death worldwide. Cancer can be caused by external factors like smoking, altered food patterns, urbanization, and prolonged post-reproductive lives. The rising incidence of kidney cancer will drive demand for kidney cancer medication in the future. In the next few years, the global kidney cancer drugs market will likely continue to grow at an increasing rate. This is due to several factors, such as the increasing geriatric population, lifestyle changes, and increased consumption of alcohol. Other than this, simple access to novel medicines is increasing kidney cancer drug use. This is mainly due to the availability of nearby stores for sedate inventory. This is necessary to increase the development of the global kidney cancer drug market. The web portal allows for the sale of medication and is used by the producers of kidney cancer drugs. It is expected that this will increase their stockpile, giving them a significant advantage over their competitors.

Market expansion is driven by the growing aging population and the increasing number of patients with kidney cancer. There are many therapeutic options, but researchers now focus more on immunotherapies and medicines. The market will continue to grow in the future due to the development of new treatments and robust pipelines. Global drug markets will be impeded by the lack of appropriate regulatory requirements for prescriptions for medication and the preference for generic, cost-effective renal cancer treatments. The drugs that kill cancer cells can also be harmful to healthy cells. Side effects include gastrointestinal problems, hair loss, exhaustion, and skin diseases. The market's growth is being held back by side effects associated with kidney cancer medication.

There has been a remarkable rise in kidney cancer cases over the past few years. The growing age of the population worldwide is expected to be a driving force for the growth of the global market for kidney cancer diagnostics. Many government agencies and private organizations around the globe are working together to raise awareness about kidney cancer. This is driving the growth of the global market for kidney cancer diagnostics. The key factor driving the growth of global kidney cancer diagnostics markets is the changing lifestyle of large parts of the world's population. Other than this, major players in the market for kidney carcinoma diagnostics have seen their revenues rise due to technological advancements, improved healthcare spending, and an advanced healthcare sector.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Kidney-Renal Cancer Drugs Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Kidney-Renal Cancer Drugs Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Amgen
  • Active Biotech AB
  • Bayer AG
  • Cipla Limited
  • F.Hoffmann-La Roche AG
  • Genetech Inc
  • Glaxosmithkline plc
  • Novartis AG
  • Onyx Pharmaceuticals Inc
  • Pfizer Inc

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Therapy Type

  • Targeted Therapy
  • Approved Drugs
  • Pipeline Drugs
  • Chemotherapy
  • Immunotherapy

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Kidney-Renal Cancer Drugs Market By Therapy Type and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Kidney-Renal Cancer Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Kidney-Renal Cancer Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Kidney-Renal Cancer Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Kidney-Renal Cancer Drugs Market, By Therapy Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Targeted Therapy
        2. Approved Drugs
        3. Pipeline Drugs
        4. Chemotherapy
        5. Immunotherapy

  • 8.   North America Kidney-Renal Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 9.   Latin America Kidney-Renal Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 10.   Europe Kidney-Renal Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.7. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 11.   Asia Pacific Kidney-Renal Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 12.   Middle East and Africa Kidney-Renal Cancer Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 13.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 14.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Amgen
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Active Biotech AB
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bayer AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Cipla Limited
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. F.Hoffmann-La Roche AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Genetech Inc
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Glaxosmithkline plc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Novartis AG
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Onyx Pharmaceuticals Inc
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Pfizer Inc
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 15.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 16.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients